# TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis

> **NCT06733519** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tharimmune Inc** · enrollment: 40 (estimated)

## Conditions studied

- Pruritus
- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Nalmefene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06733519
- **Lead sponsor:** Tharimmune Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06733519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06733519, "TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06733519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*